Search Share Prices
Ergomed appoints "expert" to enhance PrimeVigilance offering
Pharmaceutical services provider Ergomed announced on Friday a new hire has added specialist pharmacoepidemiology services to its PrimeVigilance drug safety and information offering.
The AIM-traded company said it had appointed Michael Forstner, the most recent owner and manager of Swiss-based consultancy Mesama Consulting, as head of risk management and pharmacoepidemiology.
Mesama's ongoing contracts will now be assigned to PrimeVigilance.
Stephen Stamp, Chief Executive Officer of Ergomed plc, said: "I am delighted to welcome Michael to Ergomed with his significant experience in PV services, in addition to his unique expertise in pharmacoepidemiology and risk management strategies."
Forstner is an "expertise" in pharmacovigilance (PV) stems from his experience in planning, developing, implementing and evaluating risk management studies for the safe use of medicinal products.
The company expects his appointment will build new revenue streams through the broadening of its premium service offering within PrimeVigilance.
"His appointment will add value to our PrimeVigilance services as well as providing a bridge between CRO and PV, which fits perfectly in our strategy to leverage our expertise in pharmacovigilance and late phase clinical research, and build a new revenue stream in both our PV and specialist CRO services. We remain focused on growing both of our service offerings organically and through strategic acquisitions," said Stamp.
As of 1028 BST, Ergomed's shares were up 3.49% at 237.00p.